Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction

This publication has 16 references indexed in Scilit:

• Simultaneous quantification of the new HIV protease inhibitors atazanavir and tipranavir in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry
  Journal of Chromatography B, 2004
• Activities of Atazanavir (BMS-232632) against a Large Panel of Human Immunodeficiency Virus Type 1 Clinical Isolates Resistant to One or More Approved Protease Inhibitors
  Antimicrobial Agents and Chemotherapy, 2003
• Atazanavir: a novel HIV-1 protease inhibitor
  Expert Opinion on Investigational Drugs, 2002
• Outcome and Predictors of Failure of Highly Active Antiretroviral Therapy: One‐Year Follow‐Up of a Cohort of Human Immunodeficiency Virus Type 1–Infected Persons
  The Journal of Infectious Diseases, 1999
• Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection
  New England Journal of Medicine, 1998
• High-performance liquid chromatographic determination of the antifungal drug fluconazole in plasma and saliva of human immunodeficiency virus-infected patients
  Journal of Chromatography B: Biomedical Sciences and Applications, 1995
• Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies
  European Journal of Drug Metabolism and Pharmacokinetics, 1991
• Simultaneous quantification of zidovudine and its glucuronide in serum by high-performance liquid chromatography
  Journal of Chromatography B: Biomedical Sciences and Applications, 1988
• Inactivation of human T‐cell lymphotropic virus, type III by heat, chemicals, and irradiation
  Transfusion, 1986
• Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor.
  Journal of Clinical Investigation, 1985